Affymax Stock Price, News & Analysis (OTCMKTS:AFFY)

$0.02 0.00 (0.00 %)
(As of 12/13/2017 07:51 AM ET)
Previous Close$0.02
Today's Range$0.02 - $0.02
52-Week Range$0.02 - $0.08
Volume48,610 shs
Average Volume16,685 shs
Market Capitalization$900,000.00
P/E RatioN/A
Dividend YieldN/A

About Affymax (OTCMKTS:AFFY)

Affymax logoAffymax, Inc. is a biopharmaceutical company. The Company’s product OMONTYS (peginesatide) is for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. OMONTYS is a synthetic, peptide-based erythropoiesis stimulating agent (ESA), designed to stimulate production of red blood cells. The Company has a collaboration to develop and commercialize peginesatide with Takeda Pharmaceutical Company Limited. In March 2012, the Food and Drug Administration (FDA) approved the Company’s product, OMONTYS.

Receive AFFY News and Ratings via Email

Sign-up to receive the latest news and ratings for AFFY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology


Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A


Trailing EPSN/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A


Outstanding Shares37,490,000

Affymax (OTCMKTS:AFFY) Frequently Asked Questions

What is Affymax's stock symbol?

Affymax trades on the OTCMKTS under the ticker symbol "AFFY."

Who are some of Affymax's key competitors?

Who are Affymax's key executives?

Affymax's management team includes the folowing people:

  • John A. Orwin, Independent Chairman of the Board
  • Jonathan M. Couchman, President, Chief Executive Officer, Director
  • Mark G. Thompson, Chief Financial Officer
  • Grace U. Shin J.D., General Counsel

How do I buy Affymax stock?

Shares of Affymax can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Affymax's stock price today?

One share of Affymax stock can currently be purchased for approximately $0.02.

How big of a company is Affymax?

Affymax has a market capitalization of $900,000.00.

How can I contact Affymax?

Affymax's mailing address is 19200 STEVENS CREEK BOULEVARD SUITE 240, CUPERTINO CA, 95014. The biopharmaceutical company can be reached via phone at 650-812-8700 or via email at [email protected]

MarketBeat Community Rating for Affymax (AFFY)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  112 (Vote Outperform)
Underperform Votes:  58 (Vote Underperform)
Total Votes:  170
MarketBeat's community ratings are surveys of what our community members think about Affymax and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Affymax (OTCMKTS:AFFY) Analyst Ratings History

No equities research coverage for this company has been tracked by MarketBeat


Affymax (OTCMKTS:AFFY) Earnings History and Estimates Chart

Earnings by Quarter for Affymax (OTCMKTS:AFFY)

Affymax (OTCMKTS AFFY) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2013Q113($0.66)($0.71)$63.20 million$0.84 millionViewN/AView Earnings Details
4/2/2013Q4 2012($0.61)($1.85)$14.81 million$14.77 millionViewN/AView Earnings Details
11/8/2012Q312($0.70)($0.68)$13.41 million$13.60 millionViewN/AView Earnings Details
8/8/2012($0.67)($0.89)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Affymax (OTCMKTS:AFFY) Earnings Estimates

No earnings estimates for this company have been tracked by


Dividend History for Affymax (OTCMKTS:AFFY)

No dividend announcements for this company have been tracked by

Insider Trades

Affymax (OTCMKTS AFFY) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 1.55%
Insider Trades by Quarter for Affymax (OTCMKTS:AFFY)

Affymax (OTCMKTS AFFY) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/28/2013John Peter WalkerDirectorSell16,540$1.92$31,756.80View SEC Filing  
(Data available from 1/1/2013 forward)


Affymax (OTCMKTS AFFY) News Headlines

VBI Vaccines (VBIV) vs. Affymax (AFFY) Head to Head SurveyVBI Vaccines (VBIV) vs. Affymax (AFFY) Head to Head Survey - December 12 at 1:38 AM
ARMO BioSciences Appoints Herb Cross as Chief Financial OfficerARMO BioSciences Appoints Herb Cross as Chief Financial Officer - November 28 at 11:34 AM
Head to Head Analysis: Affymax (AFFY) & Grifols (GRFS)Head to Head Analysis: Affymax (AFFY) & Grifols (GRFS) - November 26 at 3:48 AM
ContraFect Corporation (CFRX) versus Affymax (AFFY) Financial ComparisonContraFect Corporation (CFRX) versus Affymax (AFFY) Financial Comparison - October 29 at 1:08 AM
Contrasting Aevi Genomic Medicine (GNMX) & Affymax (AFFY)Contrasting Aevi Genomic Medicine (GNMX) & Affymax (AFFY) - October 22 at 4:26 PM
Affymax (AFFY) & Soligenix (SNGX) Critical ReviewAffymax (AFFY) & Soligenix (SNGX) Critical Review - September 22 at 2:20 AM
Financial Review: Mirati Therapeutics (MRTX) & Affymax (AFFY)Financial Review: Mirati Therapeutics (MRTX) & Affymax (AFFY) - September 16 at 6:14 AM
John A. Orwin Joins Retrophin Board of DirectorsJohn A. Orwin Joins Retrophin Board of Directors - March 23 at 6:48 PM
Is It Time to Buy Illumina Inc. Stock?Is It Time to Buy Illumina Inc. Stock? - March 14 at 11:39 AM

SEC Filings

Affymax (OTCMKTS:AFFY) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media


Affymax (OTCMKTS:AFFY) Income Statement, Balance Sheet and Cash Flow Statement


Affymax (OTCMKTS AFFY) Stock Chart for Wednesday, December, 13, 2017

Loading chart…

This page was last updated on 12/13/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.